Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) [0.03%]
成人B细胞急性淋巴细胞白血病自体CAR-T标准治疗后的同种异体造血干细胞移植：来自成人急性淋巴细胞白血病CAR-T真实世界结果协作组（ROCCA）的研究结果
Rawan G Faramand,Amy Zhang,Gregory W Roloff et al.
Rawan G Faramand et al.
Introduction: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor T (CAR T) cell therapy approved for adults with relapsed/refractory (r/r) B-ALL. Despite encouraging outcomes, the m...
The association between hyponatremia and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy [0.03%]
CAR-T细胞治疗后低钠血症与免疫效应细胞相关性神经毒性综合征的关联分析
Kenta Hayashino,Nobuharu Fujii,Wataru Kitamura et al.
Kenta Hayashino et al.
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis [0.03%]
Ideca诱导的100天内感染对复发/难治多发性骨髓瘤患者生存的影响：CIBMTR分析
Kitsada Wudhikarn,Lohith Gowda,Qiran Ye et al.
Kitsada Wudhikarn et al.
Background: Infections are common after chimeric antigen receptor (CAR) T-cell therapy and contribute to morbidity and mortality. While well characterized with CD19 CAR T-cells, data related to infections with B-cell matu...
Overcoming donor-specific anti-human leukocyte antigen antibodies with desensitisation in adult ex-vivo T-cell depleted haploidentical haematopoietic stem cell transplantation: a real-world analysis [0.03%]
供者特异性抗人类白细胞抗原抗体患者的敏化治疗并行外周血造血干细胞移植的疗效分析：真实世界研究
Christopher Sw Tham,Yeh Ching Linn,Liang Piu Koh et al.
Christopher Sw Tham et al.
Background: The presence of anti-human leukocyte antigen (HLA) antibodies directed against donor HLA (HLA-DSA) in HLA-mismatched haematopoietic stem cell transplantation (HCT) can affect engraftment and transplant outcome...
Hanan Alharthy,Abdulaziz Abu-Haimed,Renu E Thomas et al.
Hanan Alharthy et al.
Formal rehabilitation was required in 22% of CAR T recipients Rehabilitation utilization was associated with inferior overall survival Age, ECOG, albumin, and corticosteroid exposure independently predicted rehabilitation need CRS and ICANS...
International Survey and NGS-Based Indel Chimerism Detection of HLA Loss in Relapsed Haploidentical andMismatched Unrelated Donor Transplant Recipients [0.03%]
国际调查和基于NGS的HLA丢失检测流程在异基因造血干细胞移植后复发患者中的应用研究
Nihar Desai,Linnea Pettersson,Jinguo Wang et al.
Nihar Desai et al.
Background: HLA loss-mediated relapse is an important mechanism of relapse after haploidentical or mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell transplantation (allo-HCT), impacting the efficacy of...
Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas [0.03%]
无脾患者的CD19 CAR-T细胞治疗的安全性及疗效
Niveen Shibli,Sigrun Einarsdottir,Teng Fei et al.
Niveen Shibli et al.
Real-World Safety, Efficacy, and Immune Recovery Following Out-of-Specification Ciltacabtagene Autoleucel in Multiple Myeloma [0.03%]
不符合规范的cilta-cel治疗多发性骨髓瘤后的安全性和疗效以及免疫重建
Jesse Ritter,Danielle Bailey,Numaan Mahmood et al.
Jesse Ritter et al.
A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with/without Idarubicin Followed by Second Allogenic Stem Cell Transplant in the Treatment of Relapsed/Refractory AML/MDS Following First Allogenic Stem Cell Transplant [0.03%]
氟达拉滨、阿糖胞苷及粒细胞集落刺激素联合或不联合idarubici治疗异基因干细胞移植后复发难治的AML/MDS患者的回顾性研究并序贯二次异基因干细胞移植
Jacqueline Hsieh-Wong,Brian Pham,Joseph Tuscano et al.
Jacqueline Hsieh-Wong et al.
Background: Allogeneic stem cell transplantation (allo-SCT) remains the only curative treatment for most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Unfortunately, a significant number o...
Combination of ruxolitinib and extracorporeal photopheresis as third or subsequent line of therapy for steroid-dependent/resistant acute and chronic GVHD [0.03%]
鲁索利替尼联合体外光化学疗法治疗糖皮质激素依赖或难治性急性及慢性移植物抗宿主病的第三和后续治疗
Ziganshina Svetlana,Levkovsky Nikita,Kambaryan Nune et al.
Ziganshina Svetlana et al.